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Abstract: This article highlights the evidence linking depression to increased inflammatory drive 
and explores putative mechanisms for the association by reviewing both preclinical and clinical 
literature. The enzyme indoleamine 2,3-dioxygenase is induced by proinflammatory cytokines 
and may form a link between immune functioning and altered neurotransmission, which results 
in depression. Increased indoleamine 2,3-dioxygenase activity may cause both tryptophan deple-
tion and increased neurotoxic metabolites of the kynurenine pathway, two alterations which have 
been hypothesized to cause depression. The tryptophan-kynurenine pathway is comprehensively 
described with a focus on the evidence linking metabolite alterations to depression. The use of 
immune-activated groups at high risk of depression have been used to explore these hypotheses; 
we focus on the studies involving chronic hepatitis C patients receiving interferon-alpha, an 
immune activating cytokine. Findings from this work have led to novel strategies for the future 
development of antidepressants including inhibition of indoleamine 2,3-dioxygenase, moderating 
the cytokines which activate it, or addressing other targets in the kynurenine pathway.
Keywords: depression, inflammation, indoleamine 2,3-dioxygenase, kynurenine, serotonin, 
tryptophan
Introduction
Clinical depression is extremely common and debilitating. It is ranked by the World 
Health Organization as the fourth largest cause of burden amongst all diseases and 
the leading nonfatal disease burden.1 Current treatments have only moderate efficacy, 
with around 35% remission after initial treatment and approximately 70% remission 
after four cumulative treatment trials.2 Therefore it is necessary to look beyond cur-
rently characterized neurotransmitter systems to understand the pathophysiology of 
depression in order to produce more effective treatments in the long-term.
Emerging evidence demonstrates that: a) major depression is associated with 
increased inflammatory drive;3–5 and b) provoking an acute inflammatory response in 
healthy humans can result in depression-like behaviors and symptoms.6,7 The nature 
of these associations has yet to be delineated with respect to causality. Determining a 
plausible biological mechanism remains an important step. In this article we review 
a putative mechanism by which increased inflammation may affect mood, by altering 
activity of the enzyme indoleamine 2,3-dioxygenase (IDO).
Depression, mood, and immune functioning
There is a growing body of literature that suggests that major depression is associ-
ated with an increased inflammatory drive. People with depression display increased Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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plasma concentrations of pro-inflammatory cytokines such 
as: interleukin-1 (IL-1)3,8 (also increased in cerebrospinal 
fluid [CSF]9), interleukin-6 (IL-6),3,4,9–11 tumor necrosis 
factor (TNF)4,12 and other acute phase proteins, such as 
C-reactive protein (CRP),3 haptoglobin11 and neopterin.13 
There have been some negative findings,14,15 but the over-
all picture is sufficient to support both a positive meta-
analysis exploring the associations of CRP, IL-1, IL-6 
and depression3 and the suggestion that plasma IL-6 and 
soluble IL-2-receptor should be considered biomarkers of 
depression.16
Treatment of depression with antidepressants may 
reverse derangements in these inflammatory markers.17 
Fluoxetine treatment for depression reduces serum IL-6 in 
patients.18 Imipramine, clomipramine, venlafaxine, fluox-
etine, sertraline and trazodone have been shown to reduce 
the interferon-gamma (INF-g)/IL-10 ratio of in vitro 
human blood samples (a ratio of pro-inflammatory/anti-
inflammatory drive), consistent with an anti-inflammatory 
effect.19–21 In addition, nonresponders to selective serotonin 
reuptake inhibitor (SSRI) medication continue to exhibit 
raised IL-6 levels, raising the possibility that response to 
treatment is linked to a reduction of IL-6.22 Preliminary 
evidence also exists that an increased body temperature 
may also be present in depression and reversed by suc-
cessful treatment.23
Abnormalities of plasma cytokines may occur in various 
psychiatric disorders. In bipolar disorder, increased IL-1, 
IL-6 and TNF have been reported at differing stages of 
the illness.24 In schizophrenia, less consistent results have 
been found, but a recent meta-analysis reported increased 
plasma IL-6 and IL-1 receptor antagonist levels.25 However, 
exploring these illnesses in detail is beyond the scope of 
this review, which focuses upon the changes seen in major 
depression.
“Sickness behavior” is a characteristic constellation 
of symptoms (hypomotility, hyperthermia, hypophagia, 
hyperalgesia, decreased interest in exploration, decreased 
sexual activity, increased sleep) observed in animals fol-
lowing immune activation26–28 that has been proposed to be 
a model of depression.29 Activating an immune response 
by injecting lipopolysaccharide (LPS),30 IL-1,31 or IFN32 
results in characteristic sickness behavior. In addition, an 
acute inflammatory challenge has been reported to produce 
depression-like responses in two other animal models of 
depression, the tail suppression and sucrose consumption 
tests, after the initial illness behaviors have subsided.33 
The biochemical and behavioral effects of challenges like 
these may also be augmented by social stress,34 analogous 
to social risk factors for depression.35 Pretreatment with 
the antidepressant imipramine has been found to attenuate 
LPS-induced sickness behavior.30
Provoking an acute inflammatory response in healthy 
humans, for example via injection of endotoxin,6,7 IL-6,36 
or IFN-b,37 also produces symptoms similar to those seen 
in depression (such as fatigue, lack of motivation, anorexia, 
poor sleep). Although these symptoms are short-lived, subtle 
cognitive symptoms similar to those seen in depression are 
also present. These include feelings of social isolation6,38 
and psychomotor slowing.37 The symptoms produced by 
challenge tests such as these resolve quickly and are not 
prolonged as is seen in depression.
Immune effects on indoleamine  
2,3-dioxygenase
Indoleamine 2,3-dioxygenase (IDO) and its hepatic 
equivalent tryptophan 2,3-dioxygenase (TDO) oxygenate 
tryptophan to form kynurenine39 (Figure 1, tryptophan 
metabolic pathway). The majority of dietary tryptophan 
is metabolized through this pathway with less than 1% 
eventually being available for conversion (via hydroxyla-
tion by tryptophan hydroxylase, TPH, and decarboxylation) 
into 5HT in the brain.40 Under normal circumstances, 
TDO is the dominant enzyme, but IDO is subject to 
induction during immune activation. At such times the 
effect of increasing the combined availability of IDO and 
TDO means that the overall capacity of the kynurenine 
pathway is much increased. Therefore serum tryptophan 
concentration can be reduced by 25%–50%, leaving pro-
portionally less tryptophan available for conversion to   
serotonin.41–43
IDO is ubiquitous throughout the organs and present in 
human immune cells including macrophages and microglia.44 
Interferons are important in the induction of IDO. The sites 
of action are two IFN-stimulated response elements (ISREs) 
and IFN-g activated site (GAS) element sequences found in 
the 5′ promoter region of the IDO gene.45,46 IDO can be stimu-
lated by INF-g in macrophages and microglia.47,48 However, 
other cytokines such as TNF in combination with IL-6 or 
IL-1 can induce IDO via signal transducer and activator of 
transcription protein (STAT)-independent pathways involv-
ing p38 mitogen-activated protein kinase (p38 MAPK) and 
nuclear factor-kappa B (NF-κB).49
A proxy measure for in vivo IDO activity, like many 
enzymes, is the ratio of product:substrate (in this case 
kynurenine:tryptophan). Thus, an increase in the ratio reflects Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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greater enzyme activity, a decrease indicates lower activity 
and no change implies the same activity.50
Animal models of IDO activation 
and mood
Animal models support the hypothesis that immune-related 
sickness behavior may be related to increased activity of 
IDO. IDO activity, measured by either the plasma concen-
tration of kynurenine pathway metabolites or IDO mRNA 
expression, is increased in animal sickness behavior.51 This 
activation is partly mediated by IFN-g and TNF, since IFN-g 
knockout mice, and animals with prior treatment with the 
TNF antagonist etanercept, both show reduced IDO activa-
tion and depressive behaviors (in the forced swim and tail 
suspension tests).52 IDO knock-out mice lack the expected 
depressive behaviors secondary to an immune challenge, 
despite normal cytokine responses.51 In addition, inhibition 
of IDO blocks the depressive behavior in these models51,53 and 
administration of kynurenine induces depressive behavior in 
a dose-dependent manner.53
A human model of IDO activation 
and depression: hepatitis C cohorts 
treated with IFN-α
As described above, acute inflammatory challenges reproduce 
sickness behavior and depressive cognitions in healthy 
humans. Clearly, it is ethically difficult to continue challenges 
like these for prolonged periods due to the high degree of 
morbidity they cause. Therefore, an alternative is to study 
patient cohorts who require long-term pro-inflammatory 
treatments for an underlying condition.
An ideal high-risk population that can be used to assess 
the effects of increased inflammatory drive is chronic 
hepatitis C (HCV) patients being treated with IFN-α 
therapy. HCV is a common illness, affecting approximately 
170 million people worldwide.54,55 Without treatment, it 
causes considerable morbidity and mortality; it leads to 
chronic infection in approximately 85% of cases, cirrhosis 
in 15%–20%, and in cirrhosis patients, 1%–4% progress 
to hepatocellular carcinoma.56 HCV patients undergo an 
IFN-α-based treatment regime for between 6 and 12 months.   
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Figure 1 Tryptophan metabolic pathway.
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During this time there are high rates of depression, estimated 
at approximately 25% 57,58 and 33%59,60 (although some stud-
ies report higher prevalences, a precise figure is difficult to 
determine due to methodological differences between studies; 
those reporting higher rates report self-rated symptoms rather 
than utilizing standardized objective depression scales61).
In HCV , IFN-α increases inflammatory drive with eleva-
tions in pro-inflammatory cytokines (eg, IL-1, IL-6, IL-8 and 
TNF62,63) similar to that observed in depression.3 Although 
IFN-α is peripherally administered, increases in IFN-α, IL-6 
and monocyte chemoattractant protein-1 have been observed 
in the CSF of this group, providing evidence of central 
immunomodulatory effects. In conjunction with the increase 
in pro-inflammatory cytokines, the kynurenine:tryptophan 
ratio is increased (reflecting increased IDO activity) in both 
the blood and CSF.64,65
There are two current hypotheses regarding the mecha-
nism of how increased inflammatory drive and IDO activa-
tion may cause depression in the HCV group – tryptophan 
depletion and kynurenine toxicity.
Tryptophan depletion
Increased IDO activity should reduce the availabil-
ity of its substrate, the dietary essential amino acid 
  tryptophan.66   Serotonin (5HT) is produced from tryptophan 
via 5-  hydroxytryptophan (5HTP). Under normal conditions 
the rate-limiting enzyme tryptophan hydroxylase is only 
about 50% saturated. Therefore 5HT synthesis varies with 
tryptophan availability.67 The evidence linking 5HT dysfunc-
tion to depressive illness has been well described. Many 
effective antidepressants (such as SSRIs) work primarily on 
increasing serotonin availability in the synaptic cleft.68 This 
antidepressant effect can be temporarily reversed using the 
acute tryptophan depletion (ATD) technique, which acutely 
lowers 5HT by lowering the brain availability of its precursor 
tryptophan.69,70 Lower concentrations of plasma tryptophan 
have also been reported in depression.71 Imaging studies have 
also reported central changes in the 5HT system in depres-
sion including reduced 5HT transporters,72,73 reduced 5HT-1a 
receptors,74,75 and reduced 5HT-2a receptors.76
In the HCV cohort, reductions in plasma tryptophan 
(and 5HT, although this is an inexact measure, as much 
plasma 5HT is stored by platelets and released when they are 
stimulated, such as in venepuncture, resulting in inconsistent 
results77) have been observed.78 SSRIs are highly effective 
at treating or preventing IFN-α associated depression.79,80 
However, tryptophan does not have clear access to the 
brain from the plasma: 95% is protein-bound in the plasma, 
leaving 5% free to access the CNS.81 It is transported across 
the blood–brain barrier via active transport in competition 
with the other large neutral amino acids (LNAAs): valine, 
leucine, isoleucine, methionine, phenylalanine and tyrosine.82 
Plasma tryptophan concentrations correlate poorly with 
those of the CSF.83 Thus, a more accurate measure of brain 
tryptophan availability is the tryptophan:LNAA ratio.84 This 
ratio remains unchanged in IFN-α therapy for hepatitis C 
and does not appear to vary with depressive symptoms.64 
In keeping with this, CSF levels of tryptophan do not change 
during interferon treatment.65 However, this does not entirely 
disprove the 5HT reduction theory, as the 5HT metabolite 
5-hydroxyindoleacetic acid (5HIAA) is reduced and this 
reduction correlates with depressive symptoms.85 Therefore 
although absolute tryptophan levels appear not to be altered, 
an overall reduction in brain 5HT turnover may still be related 
to depression.
Different measures of brain 5HT functioning are required 
to further delineate these changes. A sensitive method is 
polysomnography. 5HT is important in the regulation of 
sleep86 and sleep disturbances prior to interferon treat-
ment have been suggested to predict later depression.87 
  Serotonergic compounds (such as SSRIs) increase time 
until onset of rapid eye movement (REM) sleep (increased 
REM latency). Decreasing serotonin availability, by ATD, 
has the opposite effect, decreased REM latency.88–90 Altera-
tions in REM latency have been utilized by our group to 
detect differences in physiological potency between different 
SSRIs,91 proving this technique’s sensitivity to alterations 
in central 5HT functioning. Using a within-subjects design 
we observed no significant alteration in REM latency after 
6 weeks IFN-α treatment (Pers comm, David N Christmas, 
2011). Our finding of no decrease in REM latency is similar 
to an independent study by a different group that observed 
an REM latency increase during IFN-α treatment.92 The dif-
ference between these studies has yet to be explained, but 
importantly neither observed the decrease in REM latency 
predicted by the 5HT depletion hypothesis.
An alternative explanation for the lack of decrease in 
REM latency is that IDO activation may also affect REM 
sleep via a different mechanism to 5HT depletion. Pre-
clinical evidence suggests that glutamatergic neurons are 
important in the genesis of REM sleep: indeed kynurenic 
acid (which is produced from kynurenine and is an N-methyl-
D-aspartate [NMDA] antagonist) can abolish experimentally 
induced REM sleep.93 The control of REM sleep is complex, 
with 5HT, acetylcholine, glutamate and gamma-amino 
hydroxybutyric acid (GABA) all playing important roles.94 Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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At risk of oversimplification, REM-on neurons appear to 
be glutamatergic (under tonic inhibition by GABA neu-
rons) and REM-off neurons serotonergic or noradrenergic. 
Therefore, altering the balance between kynurenic acid and 
quinolinic acid (also on the kynurenine metabolic pathway 
and an NMDA agonist [Figure 1]) may also alter both REM 
latency and duration. However, IFN-α does not alter the 
CSF kynurenic acid:quinolinic acid ratio.65 Therefore the 
preliminary conclusion is that neither central 5HT function-
ing nor NMDA activation is altered during IFN-α treatment. 
However, further research is required to form a conclusive 
picture.
Kynurenine excess
The products of IDO activation have also been hypothesized 
to cause depression. Under normal circumstances the liver 
enzyme TDO95 metabolizes tryptophan into kynurenine. TDO 
is not induced by immune activation, but is constitutively 
active and is induced by tryptophan, tyrosine, histidine, 
glucocorticoids and kynurenine. TDO primarily serves 
nicotinamide adenine dinucleotide synthesis (Figure 1) and 
is the rate-limiting enzyme of the pathway. Under circum-
stances of immune activation, IDO activity is increased, 
causing detectable increases in kynurenine and decreases 
in tryptophan.41,43,96 Kynurenine is mostly hydroxylated 
(kynurenine hydroxylase) into 3-hydroxykynurenine (3-HK). 
Kynureninase acts upon both 3-HK and kynurenine; on 3-HK 
to form 3-hydroxyanthranilic acid (3-HAA); and on kynure-
nine to form anthranilic acid (although the latter conversion 
accounts for only a minority of kynureninase activity). 
3-HAA is converted into quinolinic acid by 3-hydroxyanthra-
nilic acid oxygenase. Kynurenine can also be converted into 
kynurenic acid by kynurenine aminotransferase I and 3-HK 
into xanthurenic acid by kynurenine aminotransferase II.
Some of these kynurenine metabolites modulate neu-
rotransmission and some may be directly neurotoxic. As 
mentioned above, quinolinic acid is an NMDA agonist and 
kynurenic acid an NMDA antagonist. 3-HK is believed to 
be neurotoxic due to increased formation of reactive oxygen 
species involved in neuronal apoptosis.97,98 Quinolinic 
acid may also be neurotoxic due to increased oxidative 
stress,99,100 whereas kynurenic acid has been postulated to be 
neuroprotective.101 Under conditions of immune activation, 
preclinical evidence suggests kynurenine aminotransferase 
activity is unchanged whereas, in addition to IDO, kynure-
nine 3-hydroxylase, kynureninase and 3-hydroxyanthranilic 
acid oxygenase activity may be increased51,102 (although the 
evidence for induction of the last enzyme is contradictory, 
possibly due to species differences). Therefore, kynurenine 
metabolism is shifted toward the 3-HK/quinolinic acid 
pathway and away from the kynurenic acid pathway, which 
should result in greater neurotoxic and reduced neuropro-
tective metabolites. The relative balance of neurotoxic and 
neuroprotective pathways of kynurenine metabolism can 
be assessed indirectly in vivo by the kynurenine:kynurenic 
acid ratio.64,103
During IFN-α treatment, the plasma kynurenine:kynurenic 
acid ratio is increased and this correlates with depressive 
symptoms.64 CSF kynurenine and quinolinic acid also 
increase and these increases correlate with increases in 
depressive symptoms. However, the kynurenine:kynurenic 
acid ratio does not alter as CSF kynurenic acid also rises.65
One cross-sectional study observed increased IDO activ-
ity and a decreased kynurenic acid:kynurenine ratio (reflect-
ing a shift towards neurotoxicity) in otherwise healthy major 
depression sufferers compared to controls.104 However, as yet 
no studies have been undertaken to identify whether these 
differences resolve once the depressive episode has been 
successfully treated.
Future drug targets
Some preliminary studies have already reported possible 
efficacy of anti-inflammatory drugs in depression. A double-
blind, randomized clinical trial reported an advantage of 
reboxetine and the cyclo-oxygenase-2 inhibitor celecoxib 
over reboxetine and placebo.105 In addition, an open pilot 
study reported a benefit of augmentation with aspirin in 
depressed patients with no early response to an SSRI.106 
However, both these cases require larger more robust trials 
to prove their efficacy. A further problem may occur with 
this route; there is a large increased risk of gastrointestinal 
bleeding when SSRIs and nonsteroidal anti-inflammatory 
drugs are combined107 and cyclo-oxygenase-2 inhibitors alone 
have been associated with increased cardiovascular and all-
cause mortality above other anti-inflammatory drugs.108,109 
Therefore alternative strategies may be required to maintain 
a favorable risk–benefit ratio.
Utilizing the above evidence, it is possible to identify 
future novel pharmacological targets for antidepressants. The 
first target could be antagonizing or reducing IDO   activity. 
The drug 1-methlytryptophan can inhibit IDO and has been 
successful in reducing depressive behaviors following 
inflammatory challenges in animal models.51 Clinical trials 
using 1-methyltryptophan have commenced in humans as 
a putative anticancer agent (trial identifier NCT00567931, 
http://clinicaltrials.gov). However, there is some debate as Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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to whether it inhibits human IDO in vivo.110 In addition, IDO 
may have immunosuppressive actions in itself, highlighting 
the complexity of immune functioning.110
A different avenue may be to block the pro-inflammatory 
cytokines that are raised in depression and known to induce 
IDO. Monoclonal antibodies are available for human use, to 
treat rheumatoid arthritis or inflammatory bowel disease, to 
block both TNF (such as infliximab or etanercept) and IL-6 
(tocilizumab). Indeed, a clinical trial at Emory University 
evaluating the efficacy of infliximab in treatment resis-
tant depression is approaching completion (trial identifier 
NCT00463580, http://clinicaltrials.gov).
A third approach may be to block the downstream 
actions of excess kynurenine metabolites. As the ratio of 
NMDA receptor agonism:antagonism appears to be shifted 
towards agonism in depression, NMDA antagonists may 
have antidepressant effects. Unfortunately human subjects 
exposed to direct NMDA antagonists have experienced 
serious side effects such as sedation, memory impairment 
and psychosis.111,112 Thus design of NMDA manipulating 
compounds may require novel strategies, such as targeting 
NMDA cotransmitters. Despite this, several small stud-
ies have shown promising results for the use of ketamine, 
an NMDA receptor antagonist, for treatment-resistant 
depression.113–117
Summary
In summary, major depression appears to be accompanied 
by increases in some pro-inflammatory cytokines. In keep-
ing with this, inducing increased inflammation in animals 
or humans results in characteristic sickness behavior, or 
full-blown major depression in the high-risk HCV cohort. 
In tandem with markers of increased inflammation, IDO 
is activated, both peripherally and centrally. Although the 
evidence falls short of proving a causative link between 
inflammation, IDO and mood, the diversity and congruence 
of evidence suggests this pathway is a promising field for 
future drug targets.
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